Opioid deprescribing: rethinking policies to facilitate better patient outcomes.

IF 1.5 Q4 CLINICAL NEUROLOGY
Pain management Pub Date : 2025-07-01 Epub Date: 2025-06-09 DOI:10.1080/17581869.2025.2516409
Aili V Langford, Kellia Chiu
{"title":"Opioid deprescribing: rethinking policies to facilitate better patient outcomes.","authors":"Aili V Langford, Kellia Chiu","doi":"10.1080/17581869.2025.2516409","DOIUrl":null,"url":null,"abstract":"<p><p>Deprescribing, the patient-centered process of reducing or stopping a medication when the potential harms outweigh the likely benefits, has emerged as a promising strategy to mitigate opioid-related harm. Typically, opioid deprescribing occurs at the individual level, however, adopting a policy-driven approach could expand its reach and impact. To date, prescription opioid control policies that have been implemented with the intention of reducing opioid use and harm have often resulted in unintended consequences. In this article we discuss whether and how the concept of opioid deprescribing can be operationalized at a policy level. We review the goals, challenges and consequences of opioid control policies, explore how they intersect with system-level factors, and propose pathways for developing and implementing future opioid deprescribing policies. We argue that the development and implementation of patient-centered opioid deprescribing policies are both essential and feasible, if key challenges such as structural stigma and the complex interplay between pain and opioid use disorder are recognized and addressed. Robust evaluation frameworks will also be critical for monitoring outcomes and refining interventions. By prioritizing patient and provider needs, and carefully considering pertinent system-level factors, policymakers may be able to foster more effective and compassionate opioid management and reduce opioid-related harm.</p>","PeriodicalId":20000,"journal":{"name":"Pain management","volume":" ","pages":"413-423"},"PeriodicalIF":1.5000,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12218589/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pain management","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1080/17581869.2025.2516409","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/6/9 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Deprescribing, the patient-centered process of reducing or stopping a medication when the potential harms outweigh the likely benefits, has emerged as a promising strategy to mitigate opioid-related harm. Typically, opioid deprescribing occurs at the individual level, however, adopting a policy-driven approach could expand its reach and impact. To date, prescription opioid control policies that have been implemented with the intention of reducing opioid use and harm have often resulted in unintended consequences. In this article we discuss whether and how the concept of opioid deprescribing can be operationalized at a policy level. We review the goals, challenges and consequences of opioid control policies, explore how they intersect with system-level factors, and propose pathways for developing and implementing future opioid deprescribing policies. We argue that the development and implementation of patient-centered opioid deprescribing policies are both essential and feasible, if key challenges such as structural stigma and the complex interplay between pain and opioid use disorder are recognized and addressed. Robust evaluation frameworks will also be critical for monitoring outcomes and refining interventions. By prioritizing patient and provider needs, and carefully considering pertinent system-level factors, policymakers may be able to foster more effective and compassionate opioid management and reduce opioid-related harm.

阿片类药物处方:重新思考政策以促进更好的患者预后。
当潜在的危害超过可能的益处时,以患者为中心的减少或停止药物的处方,已经成为减轻阿片类药物相关危害的一种有希望的策略。通常,阿片类药物处方发生在个人层面,然而,采用政策驱动的方法可以扩大其范围和影响。迄今为止,为减少阿片类药物的使用和危害而实施的处方阿片类药物控制政策往往导致意想不到的后果。在本文中,我们讨论了阿片类药物处方的概念是否以及如何在政策层面上进行操作。我们回顾了阿片类药物控制政策的目标、挑战和后果,探讨了它们如何与系统级因素交叉,并提出了制定和实施未来阿片类药物处方政策的途径。我们认为,如果认识并解决结构性耻辱和疼痛与阿片类药物使用障碍之间复杂的相互作用等关键挑战,那么以患者为中心的阿片类药物处方政策的制定和实施既是必要的,也是可行的。健全的评估框架对于监测结果和完善干预措施也至关重要。通过优先考虑患者和提供者的需求,并仔细考虑相关的系统级因素,政策制定者可能能够促进更有效和更富有同情心的阿片类药物管理,并减少阿片类药物相关伤害。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Pain management
Pain management CLINICAL NEUROLOGY-
CiteScore
2.90
自引率
5.90%
发文量
62
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信